Print Page  Close Window

SEC Filings

OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 02/16/2007
Entire Document
Table of Contents

As noted, the p-values were statistically significant among all comparisons (intent-to-treat and completers) with the exception of a single comparison for the intent-to-treat population between 48mg naltrexone IR plus 400mg bupropion SR compared to 400 mg bupropion SR alone where the p-value was 0.083. Weight loss through 36 weeks, plotted for the intent-to-treat and completer populations, is as follows:
Contrave Phase IIb Mean Weight Loss Over 36 Weeks
Intent-to-Treat Population
Contrave Phase IIb Mean Weight Loss Over 36 Weeks
Completer Population
As these results imply, most patients continued to lose weight between 24 weeks and 36 weeks. No additional serious adverse events have been observed thus far during the extension portion of the trial.
We will need to conduct additional clinical trials, the results of which may not corroborate our earlier results, in order to provide enough evidence regarding efficacy and safety to submit an NDA to the FDA for potential regulatory approval. In addition, undesirable side effects of Contrave may delay or prevent regulatory approval. The most common side effects observed in our clinical trials of Contrave to date include nausea, dizziness, insomnia and headaches.